Unihealth Hospitals share price today

Unihealth Hospitals Ltd's share price was ₹543.85 at the close on 4 November 2026. It has been rising for 77 weeks. That is 3.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹158 and ₹793, and at that close it sat 61% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Unihealth Hospitals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running.

Over the last 3.1 years the share price moved +317% while the NIFTY 500 moved +26%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1. Promoters cut their stake by 4.7 points in one quarter

   From 69.5% to 64.8% in the September 2026 quarter.

3. Profit fell in the March 2026 quarter

   Profit was ₹17 crore, -5.6% on a year earlier (₹18 crore), after 3 quarters of growth.

For January to March 2026 (the quarter ended 31 March 2026), Unihealth Hospitals reported revenue of ₹65.0 crore, up 16.1% from ₹56.0 crore a year earlier, and a profit of ₹17.0 crore, down 5.6% from ₹18.0 crore.

Unihealth Hospitals results: January to March 2026 against a year earlier

The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them.

The newest call in our records is from 25 September 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.

Unihealth Hospitals closed at ₹543.85 on 4 November 2026, up 245.3% from ₹157.50 a year earlier (7 November 2025) and up 318.3% over three years. Its highest weekly close since September 2023 was ₹792.70 on 24 July 2026.

Unihealth Hospitals share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

170 weekly closes from 22 September 2023 to 4 November 2026.

4 Nov 2026: Unihealth Hospitals closed at ₹543.85, down 1.2% on the week and down 6.4% on the month. 25 Sep 2026: Unihealth Hospitals held its results call for April to June 2026. Management guided: Current-year consolidated revenue goal approximately ₹200 crore after Tanzania's delayed operational takeover.

Earlier

• Our read, 31 May 2026: FY26 consolidated revenue ₹132 Cr (+136% on a year earlier) and profit ₹46 Cr (+207% on a year earlier) driven almost entirely by the Uganda hospital at 48% operating margin; see,.,Bed capacity doubled from 200 to 400 in FY26 (Entebbe Uganda acquired + Navi Mumbai commissioned); Nashik 200-bed lease finalized, 600+ beds planned by FY27-end; see,.,H2 FY26 operating margin compressed 374 basis points to 36% vs H1's 48%, India ramp costs (depreciation, staff) loading on a small revenue base; the H1/H2 divergence is the key read on execution risk; see,.
• Results for January to March 2026: Revenue up 16.1% and profit down 5.6% on a year earlier.

Our read of the business

FY26 consolidated revenue ₹132 Cr (+136% on a year earlier) and profit ₹46 Cr (+207% on a year earlier) driven almost entirely by the Uganda hospital at 48% operating margin; see,.,Bed capacity doubled from 200 to 400 in FY26 (Entebbe Uganda acquired + Navi Mumbai commissioned); Nashik 200-bed lease finalized, 600+ beds planned by FY27-end; see,.,H2 FY26 operating margin compressed 374 basis points to 36% vs H1's 48%, India ramp costs (depreciation, staff) loading on a small revenue base; the H1/H2 divergence is the key read on execution risk; see,.

Latest quarter: India ramp costs compress H2 margins despite revenue growth; Navi Mumbai commissioned.

Our read after the latest results, written 31 May 2026.

Unihealth Hospitals has paid no dividend on the NSE since its first NSE close in our records (22 September 2023), the start of the period we checked.

No. Unihealth Hospitals Ltd paid out 0% of its profit as dividends in each of its last 7 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 25 September 2026, Unihealth Hospitals' management guided: Current-year consolidated revenue goal approximately ₹200 crore after Tanzania's delayed operational takeover.

“For the addition of 600 beds, we will require a significant amount of funding. This will be met partly through internal accruals, mainly from cash flows in Uganda; partly through bank debt; and then, for the remaining gap, we will explore or remain open to some form of QIP or preferential allotment.”Akshay Parmar, on the call for April to June 2026

What management guided

• Current-year occupancy goal 40%-45% across 400 beds; Nashik 15%-20% by year-end and Navi Mumbai above 50% by calendar year-end.
• Next financial year: 500 commissioned beds, mid-50s average occupancy and ARPOB toward ₹35,000 per occupied bed per day.
• By end-CY2028, commissioned capacity goal 1,000 beds across India and East Africa.
• FY27-28 top-line goal approximately ₹340-350 crore from about 325 occupied beds and ARPOB of ₹33,000-35,000.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 25 September 2026.

What is changing at Unihealth Hospitals, from the latest results and calls: uganda operating leverage (tax holiday + mature capacity), india greenfield ramp (navi mumbai + nashik) and super-specialty expansion in uganda (ivf, cardiac, ophthalmology).

• Uganda Operating Leverage (Tax Holiday + Mature Capacity). UMC Victoria Hospital operating margin reached 48% in H1 FY26, the Uganda 10-year tax holiday (0% corporate tax for exports) is the structural driver; margin compressed to 36% in H2 FY26 as India ramp diluted consolidated operating profit. ⚠ estimate
• India Greenfield Ramp (Navi Mumbai + Nashik). Navi Mumbai 60-bed hospital commissioned in FY26; Nashik 200-bed lease finalized. Together aiming for 500 beds in India within 24 months. ARPOB and occupancy at Navi Mumbai in FY27 H1 is the first real read. ⚠ estimate
• Super-Specialty Expansion in Uganda (IVF, Cardiac, Ophthalmology). First successful IVF twin birth at UMC Victoria Hospital in FY26 marks new specialty service activation. Higher per-procedure ARPOB from specialty services vs general hospital. ⚠ estimate
• Distribution Vertical Scale (Pharmaceutical Products in Uganda). UniHealth Uganda Limited importing and distributing pharma/medical consumables; product registrations pipeline for Reliance Life Sciences products and others, incremental high-margin revenue expected in 12 to 24 months. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 31 May 2026.

H2 FY26 operating margin at 36% vs H1's 48%, a 12pp gap. If Navi Mumbai occupancy stays below 30% through FY27, Nashik commissioning adds another fixed-cost tranche before India revenue scales.

The main risks

• India Ramp Execution Risk, Margin Dilution Extends Beyond 4 Quarters: H2 FY26 operating margin at 36% vs H1's 48%, a 12pp gap. If Navi Mumbai occupancy stays below 30% through FY27, Nashik commissioning adds another fixed-cost tranche before India revenue scales. ✓ fact
• Receivables / Cash Flow Risk (Debtor Days 306 in FY25): Debtor days expanded from 251 to 306 between FY24 and FY25. Free cash flow was −₹13 Cr in FY25 (FY24: +₹2 Cr). ✓ fact
• Currency / Geopolitical Concentration (Uganda 74% of Revenue): 74% of FY25 revenue from Uganda. Ugandan Shilling (UGX) depreciation or political instability would directly hit consolidated revenue even if local operations are unaffected. ✓ fact
• SME Exchange Liquidity / Related-Party Transaction Risk: NSE SME listing with ~1,162 shareholders (Mar 2026). Related-party transactions with UMC Hospitals Pvt Ltd, Unihealth Pharmaceuticals, UMC Global Health, Unihealth Uganda Limited. Thin float creates price volatility. ⚠ estimate

Our read after the latest results, written 31 May 2026.

When Unihealth Hospitals reports April to June 2026, these are the 4 checks that show whether the story is still on course. First: Nashik inpatient ramp from November - check marketing conversion, insurer empanelments and contribution to consolidated occupancy.

Unihealth Hospitals is not on any of our India lists this week.

Unihealth Hospitals Ltd earned ₹17.0 Cr of net profit in the Mar 2026 quarter, −5.6% on the same quarter a year earlier. Full-year FY26 profit was ₹46.0 Cr. That is 26.2% of the quarter's revenue. The same quarter a year earlier earned ₹6.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹46.0 Cr (+70.4% on the year before).

Why profit moved: revenue changed +16.1% on a year earlier and the margin moved −4.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +135.4% and revenue +68.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Unihealth Hospitals Ltd reported ₹65.0 Cr of revenue in the Mar 2026 quarter, +16.1% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 6 years it has grown 34.8% a year on average. The last full year, FY26, came in at ₹132 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Management guided 400 to 500 beds across 4 to 5 India facilities in 3 years (Nov 2024 concall). Phase 1 = Maharashtra Golden Triangle: Navi Mumbai (60 beds, commissioned FY26), Nashik (200 beds, lease signed FY26), and Pune (evaluation stage). India hospitals in the 50 to 125 bed format goal ARPOB of ~₹1 Cr/year per bed. At 60% occupancy on 60 Navi Mumbai beds, that implies ~₹36 Cr annual run-rate from a single unit, but achieving 60% occupancy in Year 1 is unlikely. The risk is India diluting consolidated EBITDA margins for 4 to 8 quarters while Uganda cash flow funds the capex.

FY26 revenue was ₹132 Cr, +33.3% on the year before.

Recent pace: the last four quarters grew +68.7% on average, against 34.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Unihealth Hospitals Ltd's operating margin was 34.0% in the Mar 2026 quarter, 4.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Over the last four quarters it has moved −5.0 percentage points. Across 7 years it has been between 10.0% and 41.0%.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Uganda contributes 73 to 74% of revenue at EBITDA margins structurally above 40%. The 10-year Uganda corporate tax holiday (available to exporters meeting the 80% export threshold) provides a direct margin floor unavailable to Indian competitors. Uganda patient volumes grew: 1,31,850 patients in FY25 vs 1,10,000 in FY24. The H1/H2 FY26 divergence (48% vs 36% EBITDA) is not Uganda-driven, it is the India ramp loading depreciation and staff costs on near-zero India revenue. Uganda's EBITDA contribution is stable; the margin compression is a denominator effect from India.

The latest quarter is within that range.

Why the margin moved: operating margin changed −5.5 percentage points on the year while gross margin changed −4.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 17% of Unihealth Hospitals Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹6.0 Cr of operating cash against ₹46.0 Cr of profit. After ₹31.0 Cr of spending on assets, free cash was −₹25.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 17% of profit came in as cash: the cash cycle got 112 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 112 days longer. The next section looks at where the cash is stuck.

Unihealth Hospitals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 304 days in FY26, up from 192 days in FY21. It spent ₹75.0 Cr on assets over the last 3 years. Customers take 341 days to pay, and stock sits for 100 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹132 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹110 Cr is tied up in the business at any time.

FY26: customers took 341 days to pay and stock sat for 100 days, about 3.3 months of sales sitting as stock, for a full cycle of 304 days, longer than FY21's 192.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 100 days. Customers pay about 341 days after that. Suppliers are paid at 138 days. Together that makes the 304-day cycle.

Spending on assets: ₹75.0 Cr over the last 3 years, against ₹18.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹10.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Unihealth Hospitals Ltd's P/E is 33.7×, near the high end of its own history: higher than 70% of past readings. Its usual P/E (the middle reading) is 28.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 46% on reported income across 6 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Unihealth Hospitals Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Unihealth Hospitals Ltd's story is not scored yet against the checks our research set on 31 May 2026. Where it sits in its own cycle: Not stated in the research file.

Still open: H2 FY26 EBITDA margin at 36% vs H1's 48%, a 12pp gap. If Navi Mumbai occupancy stays below 30% through FY27, Nashik commissioning adds another fixed-cost tranche before India revenue scales.

NOT YET CHECKED

Our read, 31 May 2026. Africa-to-India pivot in year one, Uganda cash engine funds India greenfield, but India ramp will drag near-term margins for 4 to 6 quarters.

What is proven. Africa-to-India pivot in year one, Uganda cash engine funds India greenfield, but India ramp will drag near-term margins for 4 to 6 quarters.

What is not proven yet. H2 FY26 EBITDA margin at 36% vs H1's 48%, a 12pp gap. If Navi Mumbai occupancy stays below 30% through FY27, Nashik commissioning adds another fixed-cost tranche before India revenue scales.

The test written in advance. India Ramp Execution Risk, Margin Dilution Extends Beyond 4 Quarters. Measured by: India Ramp Execution Risk, Margin Dilution Extends Beyond 4 Quarters H1 FY27 India-segment EBITDA margin (must show positive, even small, to validate ramp) by the next result.

The test written in advance. Receivables / Cash Flow Risk (Debtor Days 306 in FY25). Measured by: Receivables / Cash Flow Risk (Debtor Days 306 in FY25) CFO/OP ratio for H1 FY27 (FY25 was −6%; FY24 was +41%) by the next result.

The test written in advance. Currency / Geopolitical Concentration (Uganda 74% of Revenue). Measured by: Currency / Geopolitical Concentration (Uganda 74% of Revenue) UGX/INR exchange rate trend; Uganda political stability indicators by the next result.

What the company does. FY26 consolidated revenue ₹132 Cr (+136% YoY) and PAT ₹46 Cr (+207% YoY) driven almost entirely by the Uganda hospital at 48% EBITDA margins; see,. Bed capacity doubled from 200 to 400 in FY26 (Entebbe Uganda acquired + Navi Mumbai commissioned); Nashik 200-bed lease finalized, 600+ beds planned by FY27-end; see,. H2 FY26 EBITDA margin compressed 374 bps to 36% vs H1's 48%, India ramp costs (depreciation, staff) loading on a small revenue base; the H1/H2 divergence is the key read on execution risk; see,.

The key numbers to watch, and the level that would change the picture

Everything further down this page is evidence for or against these.

• 1 · Operating leveragebuilding
• 2 · Value-added mixquiet
• 3 · Management changequiet
• 4 · Paying down debtquiet
• 5 · Regulatory approvalquiet
• 6 · Order-book winsbuilding
• 7 · Consolidationbuilding
• 8 · Demerger or value unlockquiet
• 9 · Buybackquiet
• 10 · New geographiesbuilding
• 11 · More business from existing customersquiet
• 12 · New product launchquiet
• 13 · Mandatory normsquiet
• 14 · A bigger market to servequiet
• 15 · Market-share gainsquiet
• 16 · Asset qualityquiet

Lever 1 · Operating leverage: building. UMC Victoria Hospital EBITDA margin reached 48% in H1 FY26, the Uganda 10-year tax holiday (0% corporate tax for exports) is the structural driver; margin compressed to 36% in H2 FY26 as India ramp diluted consolidated EBITDA. What proves it keeps working: Uganda Operating Leverage (Tax Holiday + Mature Capacity). It stops working if H1 FY27 India-segment EBITDA margin (must show positive, even small, to validate ramp).

Lever 10 · New geographies: building. Navi Mumbai 60-bed hospital commissioned in FY26; Nashik 200-bed lease finalized. Together aiming for 500 beds in India within 24 months. ARPOB and occupancy at Navi Mumbai in FY27 H1 is the first real read. What proves it keeps working: India Greenfield Ramp (Navi Mumbai + Nashik). It stops working if H1 FY27 India-segment EBITDA margin (must show positive, even small, to validate ramp).

Lever 7 · Consolidation: building. First successful IVF twin birth at UMC Victoria Hospital in FY26 marks new specialty service activation. Higher per-procedure ARPOB from specialty services vs general hospital. What proves it keeps working: Super-Specialty Expansion in Uganda (IVF, Cardiac, Ophthalmology). It stops working if H1 FY27 India-segment EBITDA margin (must show positive, even small, to validate ramp).

Lever 6 · Order-book wins: building. UniHealth Uganda Limited importing and distributing pharma/medical consumables; product registrations pipeline for Reliance Life Sciences products and others, incremental high-margin revenue expected in 12 to 24 months. What proves it keeps working: Distribution Vertical Scale (Pharmaceutical Products in Uganda). It stops working if H1 FY27 India-segment EBITDA margin (must show positive, even small, to validate ramp).

Sources: our stock research file (31 May 2026) · quarterly results through Mar 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

What Unihealth Hospitals Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

1,000-Bed Goal Pushed Out · 25 September 2026. In Nov 2023, management planned 1,000 beds by the end of fiscal year 2025-26. In Sep 2026, the goal had moved to the end of calendar year 2028, representing a material multi-year delay to a core capacity plan that the latest call does not reconcile with the earlier commitment.

India Bed Commissioning Milestone Slipped · 25 September 2026. In May 2024, management planned 150 to 250 India beds by the end of Fiscal '2025. In Sep 2026, management reported that the second India facility had only just been commissioned and that total India commissioned beds were 250, indicating that the earlier milestone was achieved materially late without a specific explanation for the delay.

Nigeria Facility No Longer Reflected in Capacity Disclosure · 25 September 2026. In Nov 2023 and May 2024, management described active multi-specialty facilities in both Uganda and Nigeria. In Sep 2026, the stated 400-bed total is accounted for by 250 beds in Navi Mumbai and Nashik plus approximately 150 beds in Uganda, with Nigeria no longer reflected; the latest call does not explain the status or financial impact of this apparent change in the operating footprint.

Timeline Shift for the 1000-Bed Capacity Goal · 30 June 2026. In the Nov 2023 call, management stated they planned reaching a 1000-bed capacity from their then-current 200-bed capacity by the end of fiscal year 2025-2026. However, in the June 2026 call, having missed this timeframe and only reached 400 commissioned beds, management extended the goal completion period significantly, stating that their goal is to achieve the 1000-bed capacity by the end of the calendar year 2028.

Every quote above is taken word for word from the company’s own earnings calls.

Unihealth Hospitals Ltd earned a ROCE of 24% in FY26. That is up from a low of 14% in FY21. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 34.8% net margin and 0.52× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 34.8% net margin × 0.52× asset turnover × 1.84× leverage (assets divided by equity) ≈ 33.3% on equity. The margin does most of the work; borrowing is a big part of it.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 46% on reported income across 6 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Unihealth Hospitals Ltd had ₹33.0 Cr of borrowings against ₹138 Cr of equity in FY26, so its debt is 0.24× its equity. Its operating profit is 27 times its interest bill. Over 5 years borrowings went from ₹39.0 Cr to ₹33.0 Cr. Over the last 3 of those years it spent ₹75.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

The spending on assets is being paid for from cash, not new debt.

The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 46% on reported income across 6 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Foreign institutions cut their stake in Unihealth Hospitals Ltd by 5.6 percentage points over 6 quarters, the biggest change among its owners. Foreign institutions now own 0.0% of the company. Promoters moved −4.0 points over the same period, to 64.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: −5.6 points over 6 quarters, to 0.0%; Promoters: −4.0 points over 6 quarters, to 64.8%; Domestic institutions: −2.9 points over 6 quarters, to 0.5%.

Why the owners changed: foreign institutions drove it (−5.6 points), together with promoters (−4.0 points). They reduced their stake.

For Unihealth Hospitals Ltd, the Z-score is left out, because it comes from the second data source we could not check, and a safety score is not worth showing when two sources disagree. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

59.4 out of 100, rank 2 of 7 in Hospitals/Medical Services, with 51% of the evidence available.

Unihealth Hospitals Ltd scores 59.4 out of 100 against the 7 companies it is compared with in Hospitals/Medical Services, ranking 2. Some evidence is missing, so the score is pulled toward the middle on purpose.

The four parts add up to the total exactly: 16.8 + 18.1 + 10.5 + 14 = 59.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Unihealth Hospitals ranks 2 of 7 Hospitals/Medical Services companies on the 4-Factor Sector Score, with 59.4 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Hospitals/Medical Services, all 7 compared on one page.

Unihealth Hospitals is the 5th largest of 7 Hospitals/Medical Services companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Dr Agarwals Health Care, Park Medi World, Nephrocare Health Services and Gujarat Kidney & Super Speciality. Just below it: Gaudium IVF and Women Health and KRM Ayurveda.

Hospitals/Medical Services companies close in size

1. Dr Agarwals Health Care Ltd ₹16,144 crore
2. Park Medi World Ltd ₹9,490 crore
3. Nephrocare Health Services Ltd ₹6,180 crore
4. Gujarat Kidney & Super Speciality Ltd ₹1,288 crore
5. Unihealth Hospitals Ltd ₹875 crore
6. Gaudium IVF and Women Health Ltd ₹771 crore
7. KRM Ayurveda Ltd ₹479 crore

All 7 Hospitals/Medical Services companies, largest first

Companies close in size in other industries

1687. Permanent Magnets Ltd ₹878 crore · Shunt Resistors
1688. Bright Outdoor Media Ltd ₹875 crore · Entertainment & Media
1689. Unihealth Hospitals Ltd ₹875 crore
1690. Bizotic Commercial Ltd ₹874 crore · Trading
1691. Sastasundar Ventures Ltd ₹874 crore · Pharmacy Distribution

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.